Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 2, 2003, Pages 157-169

  Verschraagen, Miranda ^a   Boven, Epie ^b   Ruijter, Rita ^b   Van Der Born, Kasper ^b   Berkhof, Johannes ^b   Hausheer, Frederick H ^b   Van Der Vijgh, Wim J F ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIMESNA; MESNA; ONDANSETRON; PLATINUM; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESNA; MIDDLE AGED; PLATINUM; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 0037553221     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00150-4     Document Type: Article

References (32)

1. Lee KW, Martin DS. Cis-dichlorodiammineplatinum(II). Aquation equilibria and isotopic exchange of chloride ligands with free chloride and tetrachloroplatinate(II). Inorg Chim Acta 1976;17:105-10.
2. Andersson A, Hedenmalm H, Elfsson B, Ehrsson H. Determination of the acid dissociation constant for cis-diammineaquachloroplatinum (II) ion. A hydrolysis product of cisplatin. J Pharm Sci 1994;83:859-62.
3. Reedijk J, Lohman PHM. Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci 1985;7:173-80.
4. Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichloroammineplatinum (II) to DNA. Chem Biol Interact 1980;30:151-69.
5. Daley-Yates PT, McBrien DCH. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 1984;33:3063-70.
6. 2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol 1991;29:29-32.
7. Wagner T, Kreft B, Bohlmann G, Schwieder G. Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. J Cancer Res Clin Oncol 1988;114:497-501.
8. Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 1990;8:1585-90.
9. Qazi R, Chang AYC, Borch RF, Montine T, Dedon P, Loughner J, et al. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Cancer Inst 1988;80:1486-8.
10. Hospers GAP, Eisenhauer EA, De Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 1999;80:629-38.
11. Links M, Lewis C. Chemoprotectants. A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308.
12. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 1998;25:584-99.
13. Boven E, Verschraagen M, Hulscher TM, Erkelens CAM, Hausheer FH, Pinedo HM, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 2002;38:1148-56.
14. Ormstad K, Orrenius S, Låstbom T, Uehara N, Pohl J, Stekar J, et al. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res 1983;43:333-8.
15. Ormstad K, Uehara N. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett 1982;150:354-8.
16. Goren MP, Hsu LC, Li JT. Reduction of dimesna to mesna by the isolated perfused rat liver. Cancer Res 1998;58:4358-62.
17. Shaw IC, Graham MI. Mesna - a short review. Cancer Treat Rev 1987;14:67-86.
18. Leeuwenkamp OR, Neijt JP, Van der Vijgh WJ, Pinedo HM. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate. Eur J Cancer 1991;27:1243-7.
19. Ma J, Stoter G, Verweij J, Schellens JHM. Comparison of ethanol plasma protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 1996;38:391-4.
20. Verschraagen M, Zwiers THU, De Koning P, Welink J, Van der Vijgh WJF. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B 2001;753:293-302.
21. El-Yazigi A, Ernst P, Al-Rawithi S, Legayada E, Raines DA. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation. J Clin Pharmacol 1997;37:618-24.
22. James CA, Mant TGK, Rogers HJ. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 1987;23:561-8.
23. Verschraagen M, Van der Born K, Zwiers THU, Van der Vijgh WJF. Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma. J Chromatogr B 2002;772:273-81.
24. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
25. Ormstad K, Ohno Y. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat. Cancer Res 1984;44:3797-800.
26. Goren MP, Houle J-M, Bush DA, Li JT, Newman CE, Brade WP. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res 1998;4:2313-20.
27. Korst AE, Van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, Van der Vijgh WJ. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1998;4:331-6.
28. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA. Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 1981;29:658-64.
29. De Waal WAJ, Maessen FJMJ, Kraak JC. Analysis of platinum species originating from cis-diamminedichloroplatinum (II) (cisplatin) in human and rat plasma by high-performance liquid chromatography with on-line inductively coupled plasma atomic emission spectrometric detection. J Chromatogr 1987;407:253-72.
30. Repta AJ, Long DF. Reactions of cisplatin with human plasma and plasma fractions. New York: Academic Press; 1980.
31. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci 1996;85:824-7.
32. Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. Rockville (MD): Food and Drug Administration; 1999. p. 11-2.